David D. Hurd

10.2k total citations
159 papers, 4.8k citations indexed

About

David D. Hurd is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, David D. Hurd has authored 159 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Hematology, 57 papers in Oncology and 41 papers in Pathology and Forensic Medicine. Recurrent topics in David D. Hurd's work include Acute Myeloid Leukemia Research (38 papers), Lymphoma Diagnosis and Treatment (35 papers) and Hematopoietic Stem Cell Transplantation (34 papers). David D. Hurd is often cited by papers focused on Acute Myeloid Leukemia Research (38 papers), Lymphoma Diagnosis and Treatment (35 papers) and Hematopoietic Stem Cell Transplantation (34 papers). David D. Hurd collaborates with scholars based in United States, Canada and Germany. David D. Hurd's co-authors include Philip B. McGlave, Hillard M. Lazarus, Clara D. Bloomfield, B. A. Peterson, Anne I. Goldman, Norma K.C. Ramsay, John H. Kersey, William G. Woods, Tucker W. LeBien and Peter A. Cassileth and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

David D. Hurd

157 papers receiving 4.7k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
David D. Hurd 2.4k 1.6k 1.2k 990 808 159 4.8k
Joseph Brandwein 2.7k 1.1× 1.8k 1.1× 1.8k 1.5× 685 0.7× 1.0k 1.3× 191 5.3k
Thomas C. Shea 1.8k 0.8× 2.5k 1.6× 1.6k 1.4× 1.1k 1.1× 618 0.8× 172 5.6k
Jon P. Gockerman 1.1k 0.5× 1.5k 1.0× 836 0.7× 879 0.9× 908 1.1× 128 4.4k
Robert K. Stuart 3.4k 1.4× 2.0k 1.3× 2.0k 1.7× 536 0.5× 917 1.1× 198 6.9k
Pia Raanani 1.6k 0.7× 878 0.6× 1.0k 0.9× 669 0.7× 920 1.1× 305 4.2k
Peter F. Coccia 1.7k 0.7× 1.5k 1.0× 1.3k 1.1× 1.1k 1.1× 956 1.2× 108 5.7k
Sung‐Soo Yoon 1.8k 0.8× 1.5k 1.0× 1.6k 1.4× 733 0.7× 637 0.8× 342 4.2k
Éric Deconinck 1.8k 0.7× 1.7k 1.1× 702 0.6× 1.6k 1.7× 1.0k 1.3× 221 4.9k
Edward A. Copelan 3.9k 1.6× 1.4k 0.9× 878 0.7× 448 0.5× 933 1.2× 194 5.7k
Ronald Sobecks 2.2k 0.9× 1.2k 0.8× 669 0.6× 474 0.5× 624 0.8× 255 3.5k

Countries citing papers authored by David D. Hurd

Since Specialization
Citations

This map shows the geographic impact of David D. Hurd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David D. Hurd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David D. Hurd more than expected).

Fields of papers citing papers by David D. Hurd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David D. Hurd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David D. Hurd. The network helps show where David D. Hurd may publish in the future.

Co-authorship network of co-authors of David D. Hurd

This figure shows the co-authorship network connecting the top 25 collaborators of David D. Hurd. A scholar is included among the top collaborators of David D. Hurd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David D. Hurd. David D. Hurd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weisel, Katja, Anita D’Souza, David D. Hurd, et al.. (2023). P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere. 7(S3). e0036307–e0036307. 1 indexed citations
2.
Vaidya, Rakhee, et al.. (2021). Development and Implementation of Outpatient CAR-T Program at the Wake Forest Baptist Comprehensive Cancer Center. Transplantation and Cellular Therapy. 27(3). S315–S315. 1 indexed citations
3.
Pardee, Timothy S., Rebecca G. Anderson, Scott Isom, et al.. (2018). A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research. 24(9). 2060–2073. 80 indexed citations
4.
Lamar, Zanetta S., et al.. (2015). Ibrutinib and rituximab induced rapid response in refractory Richter syndrome. Clinical Case Reports. 3(7). 615–617. 10 indexed citations
5.
Pardee, Timothy S., King Lee, John Luddy, et al.. (2014). A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies. Clinical Cancer Research. 20(20). 5255–5264. 91 indexed citations
6.
Wang, Xiaofeng, Kouros Owzar, Pankaj Gupta, et al.. (2014). Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome:CALGB10105 (Alliance). British Journal of Clinical Pharmacology. 78(5). 1005–1013. 8 indexed citations
7.
Giralt, Sergio, Kenneth F. Mangan, Richard T. Maziarz, et al.. (2010). Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Annals of Oncology. 22(4). 939–946. 30 indexed citations
8.
Byrd, John C., Bercedis L. Peterson, R. Kanti, et al.. (2009). Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leukemia & lymphoma. 50(10). 1589–1596. 25 indexed citations
9.
Linker, Claudia, Kouros Owzar, Bayard L. Powell, et al.. (2009). Auto-SCT for AML in second remission: CALGB Study 9620. Bone Marrow Transplantation. 44(6). 353–359. 25 indexed citations
10.
Schuster, Michael W., E. Anaissie, David D. Hurd, et al.. (2007). Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single-dose velafermin (CG53135-05) for the prevention of oral mucositis. 5. 58–59. 2 indexed citations
11.
Miller, Antonius A., Doug Case, Paul D. Savage, et al.. (2007). Phase I Study of Lenalidomide in Solid Tumors. Journal of Thoracic Oncology. 2(5). 445–449. 21 indexed citations
12.
Keung, Yi‐Kong, et al.. (2007). Copper deficiency causes reversible myelodysplasia. American Journal of Hematology. 82(7). 625–630. 59 indexed citations
13.
Zia‐Amirhosseini, Parnian, et al.. (2007). Pharmacokinetics of Palifermin Administered as the Standard Dose and as a Collapsed Dose in Patients with Hematologic Malignancies. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 27(10). 1353–1360. 9 indexed citations
14.
15.
High, Kevin P., et al.. (2002). Low plasma concentrations of retinol and α-tocopherol in hematopoietic stem cell transplant recipients: the effect of mucositis and the risk of infection. American Journal of Clinical Nutrition. 76(6). 1358–1366. 41 indexed citations
16.
Ayash, Lois, Anthony Elias, Joseph G. Ibrahim, et al.. (1998). High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma.. Journal of Clinical Oncology. 16(3). 1000–1007. 50 indexed citations
17.
Broun, E. Randolph, Jerome L. Belinson, Jonathan S. Berek, et al.. (1994). Salvage Therapy for Recurrent and Refractory Ovarian Cancer with High-Dose Chemotherapy and Autologous Bone Marrow Support: A Gynecologic Oncology Group Pilot Study. Gynecologic Oncology. 54(2). 142–146. 15 indexed citations
18.
Frizzera, Glauco, et al.. (1994). Prognostic factors for therapeutic outcome of diffuse small non‐cleaved cell lymphoma in adults. American Journal of Hematology. 46(4). 295–303. 4 indexed citations
19.
Uhlman, Dorothy L., Clara D. Bloomfield, David D. Hurd, & B. A. Peterson. (1990). Prognostic factors at relapse for adults with acute myeloid leukemia. American Journal of Hematology. 33(2). 110–116. 26 indexed citations
20.
Hurd, David D.. (1965). Kidnap at Kiunga. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joseph Brandwein Breakdown of academic impact, for papers by Thomas C. Shea Breakdown of academic impact, for papers by Jon P. Gockerman Breakdown of academic impact, for papers by Robert K. Stuart Breakdown of academic impact, for papers by Pia Raanani Breakdown of academic impact, for papers by Peter F. Coccia Breakdown of academic impact, for papers by Sung‐Soo Yoon Breakdown of academic impact, for papers by Éric Deconinck Breakdown of academic impact, for papers by Edward A. Copelan Breakdown of academic impact, for papers by Ronald Sobecks
Rankless by CCL
2026